Antiangiogenic therapy—evolving view based on clinical trial results

摘要: Antiangiogenic therapies that target VEGF or its receptors have become a mainstay of cancer therapy in multiple malignancies. However, the clinical efficacy these agents is less than originally anticipated and, most settings, requires addition cytotoxic chemotherapy suggesting that, as for other targeted therapies, inhibitors will require selection patient subpopulations to achieve maximal benefit. Without identification and use predictive biomarkers VEGF-targeted agents, vasculature, further improvements current outcomes are unlikely. Exciting new data presented 2011 at ESMO conference showed retrospective evaluation plasma concentrations VEGF-A predicted progression-free survival and/or overall benefit from bevacizumab phase III trials certain tumour types; prospective assay required. This endeavour should be followed by biomarker research, requiring inter-laboratory collaboration high-quality, adequately powered trials.